COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

被引：2
|
作者：
Silva Miguel, L. [1 ]
de Sa, J. [2 ]
Pinheiro, B. [1 ]
Acosta, C. [3 ]
机构：
[1] CISEP Res Ctr Portuguese Econ, Lisbon, Portugal
[2] Ctr Hosp Lisboa, Lisbon, Portugal
[3] Biogen Idec Inc, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2471
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND56
引用
下载
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [2] Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Santoni, Laura
    Marchesi, Chiara
    Iannazzo, Sergio
    Cortesi, Paolo Angelo
    Piacentini, Patrizio
    Caputi, Achille Patrizio
    Mantovani, Lorenzo Giovanni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (02) : 67 - 80
  • [3] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Fumeri, G.
    Santoni, L.
    Marchesi, C.
    Iannazzo, S.
    Cortesi, R.
    Piacentini, P.
    Caputi, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2015, 18 (07) : A697 - A697
  • [4] Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Marchesi, Chiara
    Santoni, Laura
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (01) : 29 - 39
  • [5] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gasche, D.
    Restovic, G.
    Casado, V
    Ramirez-Boix, P.
    Martinez Lopez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [6] DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA: A COST-UTILITY ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A194 - A194
  • [7] BUDGET IMPACT ANALYSIS OF DELAYED-RELEASE DIMETHYLFUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Furneri, G.
    Marchesi, C.
    Santoni, L.
    VALUE IN HEALTH, 2015, 18 (07) : A700 - A701
  • [8] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [9] Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
    Viglietta, Vissia
    Miller, David
    Bar-Or, Amit
    Phillips, J. Theodore
    Arnold, Douglas L.
    Selmaj, Krzysztof
    Kita, Mariko
    Hutchinson, Michael
    Yang, Minhua
    Zhang, Ray
    Dawson, Katherine T.
    Sheikh, Sarah I.
    Fox, Robert J.
    Gold, Ralf
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2015, 2 (02): : 103 - 118
  • [10] An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate
    Sarda, S. P.
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, T.
    Okwuokenye, M.
    Kong, J.
    Zhang, R.
    Kurukulasuriya, N. C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 413 - 414
12345